Glatt, Sophie
Baeten, Dominique
Baker, Terry
Griffiths, Meryn
Ionescu, Lucian
Lawson, Alastair D G
Maroof, Ash
Oliver, Ruth
Popa, Serghei
Strimenopoulou, Foteini
Vajjah, Pavan
Watling, Mark I L
Yeremenko, Nataliya
Miossec, Pierre
Shaw, Stevan
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
https://doi.org/10.1136/annrheumdis-2017-212127
Documents that mention this clinical trial
AB0742 ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS
https://doi.org/10.1136/annrheumdis-2019-eular.765
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
https://doi.org/10.1136/rmdopen-2015-000119
SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years’ treatment
https://doi.org/10.1136/annrheumdis-2018-eular.2637
FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study
https://doi.org/10.1136/annrheumdis-2017-eular.1654
Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
https://doi.org/10.1136/bmjopen-2021-058497
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
https://doi.org/10.1136/annrheumdis-2014-205198
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2017-000582
FRI0333 ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
https://doi.org/10.1136/annrheumdis-2020-eular.4269
FRI0508 The effect of certolizumab pegol on extra-articular manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-tnf exposure
https://doi.org/10.1136/annrheumdis-2017-eular.1969
AB0747 The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1961
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
https://doi.org/10.1136/rmdopen-2014-000044
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
https://doi.org/10.1136/annrheumdis-2017-212127
Documents that mention this clinical trial
AB0742 ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS
https://doi.org/10.1136/annrheumdis-2019-eular.765
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
https://doi.org/10.1136/rmdopen-2015-000119
SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years’ treatment
https://doi.org/10.1136/annrheumdis-2018-eular.2637
FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study
https://doi.org/10.1136/annrheumdis-2017-eular.1654
Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
https://doi.org/10.1136/bmjopen-2021-058497
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
https://doi.org/10.1136/annrheumdis-2014-205198
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2017-000582
FRI0333 ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
https://doi.org/10.1136/annrheumdis-2020-eular.4269
FRI0508 The effect of certolizumab pegol on extra-articular manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-tnf exposure
https://doi.org/10.1136/annrheumdis-2017-eular.1969
AB0747 The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1961
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
https://doi.org/10.1136/annrheumdis-2017-212127
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
https://doi.org/10.1136/rmdopen-2014-000044
Documents that mention this clinical trial
AB0742 ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS
https://doi.org/10.1136/annrheumdis-2019-eular.765
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
https://doi.org/10.1136/rmdopen-2015-000119
SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years’ treatment
https://doi.org/10.1136/annrheumdis-2018-eular.2637
FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study
https://doi.org/10.1136/annrheumdis-2017-eular.1654
Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
https://doi.org/10.1136/bmjopen-2021-058497
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
https://doi.org/10.1136/annrheumdis-2014-205198
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2017-000582
FRI0333 ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
https://doi.org/10.1136/annrheumdis-2020-eular.4269
FRI0508 The effect of certolizumab pegol on extra-articular manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-tnf exposure
https://doi.org/10.1136/annrheumdis-2017-eular.1969
AB0747 The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1961
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
https://doi.org/10.1136/annrheumdis-2017-212127
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
https://doi.org/10.1136/rmdopen-2014-000044
Funding for this research was provided by:
UCB Pharma